Development and assessment of the efficacy and safety of human lung-targeting liposomal methylprednisolone crosslinked with nanobody

• Main Authors: Dong Weng (Author), Zhao-Fang Yin (Author), Shan-Shan Chen (Author), Xian He (Author), Nan Li (Author), Tao Chen (Author), Hui Qiu (Author), Meng-Meng Zhao (Author), Qin Wu (Author), Nian-Yu Zhou (Author), Li-Qin Lu (Author), Dan-Li Tang (Author), Jia-Cui Song (Author), Hui-Ping Li (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Glucocorticoid (GC) hormone has been commonly used to treat systemic inflammation and immune disorders. However, the side effects associated with long-term use of high-dose GC hormone limit its clinical application seriously. GC hormone that can specifically target the lung might decrease the effective dosage and thus reduce GC-associated side effects. In this study, we successfully prepared human lung-targeting liposomal methylprednisolone crosslinked with nanobody (MPS-NSSLs-SPANb). Our findings indicate that MPS-NSSLs-SPANb may reduce the effective therapeutic dosage of MPS, achieve better efficacy, and reduce GC-associated side effects. In addition, MPS-NSSLs-SPANb showed higher efficacy and lower toxicity than conventional MPS.

Item Description

1071-7544
1521-0464
10.1080/10717544.2021.1921073